Lisata Therapeutics to Present at a Major Investment Showcase
Lisata Therapeutics, Inc. (NASDAQ: LSTA), a clinical-stage pharmaceutical company devoted to creating innovative therapies for serious diseases, recently shared exciting news about its upcoming presentation at the Investival Showcase USA. This event is set for March 10-11, attracting industry leaders and experts from around the globe.
Event Details
David J. Mazzo, Ph.D., the President and CEO of Lisata Therapeutics, will deliver a corporate overview aiming to enlighten attendees about the company’s vision and objectives. Scheduled for March 11, Dr. Mazzo’s presentation will take place at 11:30 a.m. Eastern Time. This is a valuable opportunity for investors and industry stakeholders to gain insight into Lisata's strategic plans and innovations.
The Mission of Lisata Therapeutics
Lisata Therapeutics is committed to discovering and developing groundbreaking therapies geared towards treating advanced solid tumors and other significant diseases. Their flagship product candidate, certepetide, is positioned at the forefront of cancer treatment innovations. This investigational drug leverages a unique uptake pathway, enhancing the efficacy of co-administered anti-cancer therapies by ensuring they reach their targets within solid tumors.
Innovative Drug Development
The company’s approaches blend scientific expertise with the latest advancements in drug delivery systems. By utilizing the CendR Platform technology, Lisata Therapeutics stands out in the crowded pharmaceutical field. They have established promising R&D partnerships that pave the way for impactful therapeutic solutions.
Anticipated Milestones and Future Outlook
Lisata Therapeutics is poised to unveil several pivotal developments over the next 1.5 years. The company is optimistic about its financial standing, expecting its current capital resources to support operations through the second quarter of 2026. This timeline includes several anticipated milestones from ongoing and planned clinical trials, marking a crucial period of growth and opportunity.
Understanding Certepetide’s Mechanism
For those interested in the intricate details of how certepetide functions, the company has developed engaging educational resources. These aids aim to illustrate the drug's mechanism of action, enhancing understanding of its potential impact on cancer treatment strategy.
Connecting with Lisata Therapeutics
For more information regarding Lisata Therapeutics, including updates on their research and advancements, visit their official website. The company encourages open communication and is eager to engage with stakeholders who share a passion for medical innovation.
Contact Information
If you have inquiries, you can reach out to Lisata Therapeutics directly. For investor relations, contact John Menditto, Vice President of Investor Relations and Corporate Communications, at 908-842-0084 or via email at jmenditto@lisata.com. For media inquiries, please connect with Elizabeth Coleman at ICR Healthcare by calling 203-682-4783 or emailing elizabeth.coleman@icrhealthcare.com.
Frequently Asked Questions
What is the purpose of the Investival Showcase?
The Investival Showcase serves as a platform for emerging pharmaceutical companies to present their innovations and engage with potential investors and industry professionals.
Who is David J. Mazzo?
David J. Mazzo, Ph.D., is the President and CEO of Lisata Therapeutics, with extensive experience in the pharmaceutical industry.
What is certepetide?
Certepetide is an investigational drug developed by Lisata Therapeutics aimed at improving the delivery of anti-cancer therapeutics to solid tumors effectively.
When is Lisata's presentation at the showcase?
Lisata's presentation is scheduled for March 11 at 11:30 a.m. Eastern Time during the conference.
How can I learn more about Lisata Therapeutics?
Visit Lisata’s official website or contact their Investor Relations team for the latest updates and detailed information about their projects.
